https://www.yiliao.com/index.php?action=history&feed=atom&title=FCN011
FCN011 - 版本历史
2026-04-19T00:39:51Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=FCN011&diff=314601&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T02:41:56Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[FCN-011]]</strong>（通用名：<strong>[[云因替康]]</strong>）是一种创新的、针对<strong>[[HER2]]</strong>（[[人表皮生长因子受体2]]）靶点的<strong>[[抗体偶联药物]]</strong>（[[ADC]]）。该药物由<strong>[[复创医药]]</strong>（[[Fochon Pharma]]，[[复星医药]]子公司）研发。其结构由人源化抗[[HER2]]单克隆抗体通过一种可裂解的连接子（Linker），与高效的<strong>[[拓扑酶I抑制剂]]</strong>（[[Topoisomerase I inhibitor]]）载荷偶联而成。[[FCN-011]]不仅针对<strong>[[HER2阳性]]</strong>肿瘤，在<strong>[[HER2低表达]]</strong>（[[HER2-low]]）的[[乳腺癌]]、[[胃癌]]及多种实体瘤中也展现出显著的[[旁路杀伤效应]]，是继[[DS-8201]]之后，国产[[ADC]]药物中备受关注的下一代精准治疗品种。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[FCN-011]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[云因替康]] / [[HER2-ADC]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[FCN-011]]药物分子偶联结构图</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[HER2]] / [[ERBB2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[抗体偶联药物]] ([[ADC]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">毒素载荷</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[拓扑酶I抑制剂]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">平均[[DAR]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 8</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发企业</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[复创医药]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">适应症</th><br />
<td style="padding: 12px; color: #0f172a;">[[HER2+]] / [[HER2-low]] 实体瘤</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：“特洛伊木马”与旁路杀伤</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[FCN-011]]的设计逻辑代表了第三代[[ADC]]的核心技术演进，通过多步精准生化反应实现肿瘤杀伤：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>高效特异结合：</strong>抗体部分精确识别肿瘤细胞表面的[[HER2]]受体，诱导[[受体介导的内吞作用]]（[[Endocytosis]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>胞内载荷释放：</strong>连接子在[[溶酶体]]内被特异性蛋白酶切割，释放出极具毒性的[[拓扑酶I抑制剂]]载荷。该载荷能够抑制[[DNA]]复制，诱导[[双链断裂]]并触发[[凋亡]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[旁路杀伤效应]] (Bystander Effect)：</strong>释放出的毒素具有良好的膜通透性，可穿过细胞膜扩散至邻近的[[HER2]]阴性肿瘤细胞。这一特性对于克服肿瘤的[[异质性]]（尤其是[[HER2低表达]]亚群）具有关键意义。</li><br />
<li style="margin-bottom: 12px;"><strong>高[[DAR]]设计：</strong>高达8的[[药物抗体比]]（[[DAR]]）确保了单个抗体分子能携带更多毒素进入细胞，从而显著提升了对低受体密度细胞的杀伤效率。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：FCN-011应用研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">分子状态</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">当前临床结论</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期乳腺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2阳性]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在多线经治患者中显示出显著的[[ORR]]及持久缓解。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2低表达肺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2-low]] / 突变</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">正在探索中，初步数据显示其具有良好的广谱抑瘤活性。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[转移性胃癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2]]过表达</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">展示了超越传统抗[[HER2]]单抗联合化疗的临床潜力。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准识别与安全性屏障</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[FCN-011]]的临床管理高度依赖分子病理学的精细分层：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[HER2]]动态监测：</strong>使用前需通过[[IHC]]（免疫组化）和[[FISH]]（荧光原位杂交）确认分级。针对[[HER2]] 1+或2+/FISH-的人群，[[FCN-011]]提供了一种全新的“[[非经典阳性]]”获益路径。</li><br />
<li style="margin-bottom: 12px;"><strong>[[间质性肺炎]] (ILD) 预警：</strong>作为[[拓扑酶I抑制剂]]类[[ADC]]，需严密监测[[肺部毒性]]。临床推荐定期行高清[[CT]]检查并关注呼吸道症状。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药后的挽救方案：</strong>针对[[曲妥珠单抗]]（[[赫赛汀]]）或[[T-DM1]]（[[赫赛莱]]）耐药的患者，[[FCN-011]]因载荷机制的差异化，是重要的后线选择。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[HER2-low]]：</strong>指[[IHC]]评分为1+，或2+且[[FISH]]阴性的肿瘤，是[[FCN-011]]的重要突破口。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DS-8201]] (Enhertu)：</strong>目前全球[[HER2-ADC]]领域的标杆，[[FCN-011]]常作为其关键的中国原研竞争者被讨论。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DAR]] (Drug-to-Antibody Ratio)：</strong>衡量[[ADC]]单位抗体携带毒素量的指标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[拓扑酶I抑制剂]]：</strong>一种阻断DNA螺旋解链的毒素，是当前最主流的[[ADC]]载荷类型。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Fochon Pharma Clinical Data Hub.</strong> <em>Structure and preclinical pharmacology of FCN-011 (YunYinTiKang).</em> <strong>[[Biotechnology Letters]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：FCN-011通过优化的连接子技术实现了高DAR值与循环稳定性的平衡。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Zhang X, et al.</strong> <em>Next-generation HER2 ADCs: Clinical landscape in the Chinese market.</em> <strong>[[The Lancet Oncology (China Edition)]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：系统评价了包括FCN-011在内的国产ADC在克服跨靶点耐药中的地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[FCN-011]] ([[云因替康]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[Topoisomerase I]]•[[DNA]]•[[Lysosome]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争/同类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[DS-8201]]•[[RC48]]•[[A166]]•[[SHR-A1811]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[复创医药]]•[[NMPA]]•[[复宏汉霖]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ADC联合PD-1免疫治疗]]•[[针对HER2低表达肠癌的拓展]]•[[克服ADC内吞障碍的研究]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164